Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer

被引:0
|
作者
Mantz, CA
Vokes, EE
Stenson, K
Kies, MS
Mittal, B
Witt, ME
List, MA
Weichselbaum, RR
Haraf, DJ
机构
[1] Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[3] Univ Chicago, Dept Surg, Chicago, IL 60637 USA
[4] Univ Chicago, Ctr Canc Res, Chicago, IL 60637 USA
[5] Northwestern Univ, Dept Radiat Oncol, Chicago, IL 60611 USA
[6] Northwestern Univ, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA
来源
CANCER JOURNAL | 2001年 / 7卷 / 02期
关键词
oropharyngeal cancer; chemoradiotherapy; chemotherapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE Locoregionally advanced oropharyngeal cancer has been conventionally treated with either surgery and adjuvant radiotherapy or radiotherapy alone, and clinical and functional outcomes have been pear. Chemoradiotherapy has been demonstrated to improve functional outcome and disease control over conventional treatment in recent randomized head and neck trials. Herein, we report overall survival, progression-free survival, and patterns of failure in locoregionally advanced oropharyngeal cancer treated with induction chemotherapy with or without conservative surgery followed by concomitant chemoradiation. MATERIALS AND METHODS Three cycles of induction chemotherapy consisting of cisplatin, 5-fluorouracil, leucovorin, and interferon alpha -2b (PFL-IFN) were followed by conservative, organ-sparing surgery for residual disease. All patients then proceeded to concomitant chemoradiation consisting of seven or eight cycles of 5-fluorouracil, hydroxyurea, and a total radiotherapy dose of roughly 7000 cGy. RESULTS Sixty-one patients with predominantly stage IV disease were treated. Clinical complete response was observed in 65% of patients after induction therapy. The median follow-up was 68.0 months for survivors and 39.0 months for all patients. At 5 years, overall survival is 51%, progression-free survival is 64%, locoregional control is 70%, and distant control is 89%. Locoregional recurrence accounted far 80% of all initial failures. Only five radical surgeries (none were total glossectomy) were performed for initial disease control. Treatment-related toxicity accounted for four deaths. CONCLUSION PR-IFN given with 5-fluorouracil, hydroxyurea, and radiotherapy produces a high rate of cures with organ preservation in a disease group that has traditionally fared poorly. Local and distant disease control and survival rates exceed those observed with more standard treatment approaches involving surgery and radiotherapy. Further investigation into chemoradiotherapy as a curative modality for this disease is warranted.
引用
收藏
页码:140 / 148
页数:9
相关论文
共 50 条
  • [1] Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer
    Oh, JL
    Vokes, EE
    Kies, MS
    Mittal, BB
    Witt, ME
    Weichselbaum, RR
    Haraf, DJ
    ANNALS OF ONCOLOGY, 2003, 14 (04) : 564 - 569
  • [2] Sequential induction chemotherapy and concomitant chemoradiotherapy in the management of locoregionally advanced laryngeal cancer
    Mantz, CA
    Vokes, EE
    Kies, MS
    Mittal, B
    Witt, ME
    List, MA
    Weichselbaum, RR
    Haraf, DJ
    ANNALS OF ONCOLOGY, 2001, 12 (03) : 343 - 347
  • [3] INDUCTION CHEMOTHERAPY FOLLOWED BY CONCOMITANT CHEMORADIOTHERAPY IN ADVANCED HEAD AND NECK CANCER
    Karacetin, D.
    Okten, B.
    Maral, O.
    Incekara, O.
    Aslan, M.
    Aykanat, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 224 - 224
  • [4] Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy in locoregionally advanced head and neck cancer
    Seol, Y.
    Jin, C. Y. J. Choi Yong
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S769 - S769
  • [5] Induction chemotherapy followed by concomitant chemoradiotherapy in locally advanced rectal carcinoma
    Halim, Inas Ibraheim Abdel
    El-Sadda, Wael
    El Ebrashy, Mosta
    El Nahas, Waleed
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Induction chemotherapy followed by concomitant chemoradiotherapy for locally advanced nasopharingeal carcinoma
    Ferrari, D
    Rocca, A
    Jereczek-Fossa, B
    Orecchia, R
    Carbone, C
    Fumagalli, L
    Luciani, A
    Giugliano, G
    Tredici, P
    Foa, P
    ANNALS OF ONCOLOGY, 2005, 16 : 297 - 297
  • [7] Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer
    Marti, Jennifer L.
    Hochster, Howard S.
    Hiotis, Spiros P.
    Donahue, Bernadine
    Ryan, Theresa
    Newman, Elliot
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (12) : 3521 - 3531
  • [8] Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma
    Liu, Li-Ting
    Liang, Yu-Jing
    Guo, Shan-Shan
    Mo, Hao-Yuan
    Guo, Ling
    Wen, Yue-Feng
    Xie, Hao-Jun
    Tang, Qing-Nan
    Sun, Xue-Song
    Liu, Sai-Lan
    Li, Xiao-Yun
    Yang, Jin-Hao
    Yang, Zhen-Chong
    Tang, Lin-Quan
    Chen, Qiu-Yan
    Mai, Hai-Qiang
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [9] Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer
    Jennifer L. Marti
    Howard S. Hochster
    Spiros P. Hiotis
    Bernadine Donahue
    Theresa Ryan
    Elliot Newman
    Annals of Surgical Oncology, 2008, 15 : 3521 - 3531
  • [10] Metabolomic Insight into Implications of Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Locally Advanced Head and Neck Cancer
    Boguszewicz, Lukasz
    Bielen, Agata
    Ciszek, Mateusz
    Skorupa, Agnieszka
    Mrochem-Kwarciak, Jolanta
    Skladowski, Krzysztof
    Sokol, Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)